US FDA’s Latest Review Of Stealth’s Elamipretide Will Move With Speed

 
• By Kevin Grogan
  
Racetrack
US FDA expects to make a regulatory decision on Stealth's elamipretide NDA resubmission in just over a month. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Product Reviews

More from Pink Sheet